KLBF - To increase products' ASP due to IDR depreciation

KLBF - To increase products' ASP due to IDR depreciation Kalbe Farma (KLBF) is considering to increase its products' average selling price (ASP) due to further IDR depreciation vs USD and has led to higher input costs for KLBF as most of its raw materials are imported. Note that, around 90% of the materials used in KLBF's production process are imported, with a significant portion comprising Active Pharmaceutical Ingredients (API) and raw materials for dairy products. These imports originate from various countries across Asia, Australia, and Europe. However, KLBF emphasizes that any such action as increasing its product' ASP, will be executed selectively. Moreover, to mitigate currency fluctuations, the company is actively working on optimizing the development of products utilizing local resources, including herbal medicines and biosimilars. This commitment to boosting the use of domestic raw materials is exemplified by the launch of the anemia drug Efepoetin Alfa (Efesa), entirely manufactured in Indonesia. Efesa, the world's first anemia medication for chronic kidney disease patients, recently obtained regulatory approval and is slated for export. (Source : Bisnis Indonesia)